Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + etoposide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + etoposide is a combination chemotherapy regimen used primarily in the treatment of various cancers, including small-cell lung cancer (SCLC) and relapsed or refractory non-Hodgkin lymphoma (NHL). Gemcitabine is a nucleoside analog that acts as a nucleoside metabolic inhibitor. It is phosphorylated within cells to active metabolites that are incorporated into DNA, leading to masked chain termination and apoptosis of malignant cells. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks by stabilizing the enzyme-DNA complex, preventing religation of DNA strands during replication. The combination has demonstrated activity in SCLC and NHL with manageable toxicity profiles, providing palliative benefit especially for patients who may not tolerate more aggressive regimens[2][5][8].
- Other names
- gemcitabine + etoposide
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)RNR (Ribonucleotide reductase)DNA polymerase family
Beyond the preview
Go deeper on gemcitabine + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + etoposide.